Compare ASC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | NGNE |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 744.9M |
| IPO Year | 2013 | 2014 |
| Metric | ASC | NGNE |
|---|---|---|
| Price | $17.31 | $36.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $17.00 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 592.9K | 194.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.31 | $15.93 |
| 52 Week High | $20.03 | $43.66 |
| Indicator | ASC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 47.83 | 51.43 |
| Support Level | $15.04 | $18.24 |
| Resistance Level | $17.81 | $43.66 |
| Average True Range (ATR) | 0.62 | 2.66 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 37.12 | 58.04 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.